Doncaster man is first in Europe to benefit from new arthritis drug trial
Friday 20 December 2013
A Doncaster man suffering from severe arthritis is benefitting from the trial of a new drug at Doncaster and Bassetlaw Hospitals.
In October, 63-year old Peter Wynne, of Clay Lane in Doncaster, who suffers severe rheumatoid arthritis in his hands, knees and shoulders, agreed to take part in the ‘Ascertain trial’ after he was contacted by Consultant Rheumatologist, Dr Chee-Seng Yee of Doncaster and Bassetlaw Hospitals.
Mr Wynne was the first person in Europe to sign up for the trial, which will see if the drug can help control the severe Rheumatoid arthritis he suffers.
As part of the trial Mr Wynne has been receiving fortnightly injections of the trial drug, known as Surilumab. It is hoped that the Surilumab – a biologic drug that targets a specific molecule that can cause arthritic inflammations - will help ease Mr Wynne’s condition.
Mr Wynne said: “I’m very glad that I’ve taken part in this trial as I am already seeing results. I’ve suffered with arthritis since my forties but in recent weeks the arthritis in my hands has improved and I am feeling a lot better in myself too.
“When Dr Yee asked me if I wanted to take part in the trial I thought it was worth a shot and if it worked, would not only benefit me, but many other people in the future. I’m very glad that I went for it.”
The Ascertain trial is one of several clinical trials that Dr Yee is hoping to bring to Rheumatology patients of Doncaster and Bassetlaw Hospitals.
Dr Yee added: “It’s great that Mr Wynne’s arthritis is responding well and hopefully that will continue for him. When I came to Doncaster and Bassetlaw Hospitals I wanted to bring in more clinical trials like this. The Department of Rheumatology and the Trust’s Research and Development team has made it possible.
“Doncaster and Bassetlaw Hospitals is very progressive with its outlook on Research and Development, which is good news for patients as more and more often we are able to provide people with new or alternative treatments.
“It is also a very positive thing for patients to be involved in, as trials can break the cycle of treatment that patients may be experiencing. Many patients are also very happy to know that they are part of a process that could bring long-term benefits to many people with their condition in the future.”
Peter Wynne will take part in the Ascertain trial until April 2014 but will be allowed to carry on taking the drug beyond then if he wishes too.
Anyone who is interested in finding out more about Doncaster and Bassetlaw Hospitals Research and Development, and wants to find out more about other trials that are being carried out should contact the Research and Development department via 01302 366666.